Alduaij W et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117(17):4519-29. Abstract
Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014;15(4):424-35. Abstract
Béguelin W et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013;23(5)677-92. Abstract
Bödör C et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013;122(18):3165-8. Abstract
Davies A et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): A randomised, open-label, phase 3 trial. Lancet Oncol 2017;4(6):e272-82. Abstract
Dreyling M et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 2017;35(35):3898-905. Abstract
Flinn IW et al. DYNAMO: A Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37(11):912-22. Abstract
Gan L et al. Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential. Biomark Res 2018;6:10. Abstract
Gopal AK et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18. Abstract
Italiano A et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study. Lancet Oncol 2018;19(5):649-59. Abstract
Lampson BL et al. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 2017;26(11):1267-79. Abstract
Leonard JP et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37(14):1188-99. Abstract
Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017;377(14):1331-44. Abstract
Morschhauser F et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379(10):934-47. Abstract
Mössner E et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115(22):4393-402. Abstract
Niederfellner G et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011;118(2):358-67. Abstract
Townsend W et al. Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: Four-year results from the phase III GALLIUM study. ASH 2018;Abstract 1597.